copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
GenSight Biologics – Leader in Gene Therapy Against Blindness GenSight Biologics Co-Founder José-Alain Sahel and colleague Botond Roska were awarded the 2024 Wolf Prize in Medicine for pioneering work on optogenetics -- the core technology of GS030
GeneSight May Help Gain Mental Health Meds Insights GeneSight Psychotropic is a pharmacogenomic test which means that it analyzes how your genes may affect medication outcomes The GeneSight test analyzes clinically important genetic variations in your DNA Results can inform your healthcare provider about how you may break down or respond to certain medications commonly prescribed to treat depression, anxiety, ADHD, and other psychiatric
GenSight Biologics Announces Regulatory Approval for GS010 LUMEVOQ . . . About GenSight Biologics GenSight Biologics S A is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders
GenSight Biologics to Launch Phase II LHON Gene Therapy Trial in France The regulatory approval of this open-label, dose-ranging Phase II trial, dubbed REVISE, will support the agency's ongoing review of GenSight's application for the named-patient early-access program, the company said this week GenSight plans to launch the REVISE study at a single center in France in January and enroll 14 patients
GenSight Biologics Lumevoq 5-year Outcomes | Retinal Physician GenSight Biologics announced the publication of outcomes data from 5 years’ follow-up of patients treated unilaterally with Lumevoq, the company’s investigational gene therapy for Leber hereditary optic neuropathy (LHON) due to a mutated ND4 mitochondrial gene
GenSight Biologics (EPA:SIGHT) Company Profile Description GenSight Biologics S A , a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system
Company Overview – GenSight Biologics GenSight Biologics S A is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders
GenSight Biologics Announces Regulatory Approval for GS010 LUMEVOQ About GenSight Biologics GenSight Biologics S A is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders
GenSight Biologics Secures $500K to Propel Next-Generation Vision . . . As a clinical-stage biotechnology company, GenSight Biologics is committed to transforming the treatment landscape for conditions that cause irreversible vision loss, particularly for patients suffering from severe degenerative retinal diseases